OR WAIT null SECS
IRVING, Texas -- Novation, a leading healthcare contracting services company of VHA Inc., University HealthSystem Consortium (UHC) and Provista, LLC., and Becton Dickinson (BD) announced today that they have agreed to add the BD GeneOhm molecular products to the microbiology portfolio effective April 15, 2008. This includes the PCR instrument and assays for hospital surveillance of methicillin-resistant Staphylococcus aureus (MRSA). The identification and control of hospital-acquired infections (HAIs) have become an important initiative for facilities.
“The BD GeneOhm molecular-based test is a cost-effective and efficient way for a medium to high volume screening program,” said, Cheryl Mason, portfolio executive at Novation.
Novation recently launched its MRSA Solutions Set, a comprehensive online resource program that provides healthcare workers with contract solutions available through Novation’s extensive portfolio to prevent, detect and treat the infection. The program is designed to be a one-stop, all-inclusive repository of Novation contracts, supplier resources, and industry-approved clinical guidelines. The resource is part of a larger infection control portfolio which provides support for members in their fight against all HAIs.